Thermo Fisher Scientific expands viral vector manufacturing capabilities with Plainville facility
Thermo Fisher Scientific’s new Plainville, MA viral vector manufacturing facility has opened, expanding the company's cell and gene therapy capabilities with advancing bioproduction and analytical instrumentation technologies.
Scientific services provider Thermo Fisher Scientific has opened the doors to its new viral vector manufacturing facility in Plainville, MA, expanding its cell and gene therapy capabilities with a new state-of-the-art facility with the addition of a 300,000 square foot site adding approximately 300 jobs in support of the development, testing, and manufacturing of viral vectors – critical components in gene therapies.
The Plainville facility will greatly expand Thermo Fisher’s viral vector capacity to six sites across the United States and Europe, featuring a sustainable design, flexible laboratory and production suites, warehousing, and office space. It will also advance the company’s bioproduction and analytical instrumentation technologies. As part of an investment strategy hoping to provide fully integrated capabilities to connect the cell and gene therapy value and supply chain, the facility will also provide translational sciences labs for early-stage development, viral vector services, and cell therapy manufacturing with integrated packaging and distribution services, amongst others. More than 130 viral vector products have been produced by Thermo Fisher for the treatment of cancer, blood disorders, and other genetic diseases.
Chairman, President, and CEO of Thermo Fisher Scientific Marc N. Casper stated: "Plainville is an impressive addition to our pharma services network as we continue to invest and innovate cell and gene therapy services, products, and workflows... We are enabling our customers to speed their scientific discoveries in cell and gene therapy while also supporting their manufacturing needs, whether they are early in the development process or ready to transition to clinical or commercial scale.”
The new Patheon Quick to Clinic viral vector manufacturing platform is an additional all-inclusive manufacturing platform that uses IND-ready processes for lentivirus and adeno-associated virus manufacturing for rapid process development, further accelerating the discovery-to-clinic pipeline.
Congressman Jack Auchincloss concluded: “Massachusetts is the world capital of life sciences, with a footprint of biomedical innovation that extends well beyond Cambridge and Boston... Thermo Fisher Scientific’s new, state-of-the-art viral vector manufacturing facility in Plainville is a clear statement from a world-class company that the Commonwealth is not just the leader in R&D, but also in biomanufacturing.”
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance